de Oliveira R.P.B.,Rio de Janeiro State Federal University |
Iglesias A.C.,Hospital Universitario Gaffree Guinle |
de Oliveira C.A.S.,Pontifical Catholic University of Rio de Janeiro |
Pannain V.L.N.,Federal University of Rio de Janeiro
Revista do Colegio Brasileiro de Cirurgioes | Year: 2015
Objective: To evaluate the applicability of the main categories of risk and morphological factors in the prognosis of gastrointestinal stromal tumors. Methods: we retrospectively studied fifty-four cases of GIST, assessing the main prognostic factors of this neoplasis: risk levels, topography, size, mitotic index, necrosis, histological subtype and immunophenotype. We also verified their association and the reduction of overall survival. Results: Univariate analysis showed that tumors with mitoses number greater than 5 per 50CGA (high-power fields), the presence of necrosis and a high risk for both the systems proposed by Fletcher and Miettinen had a significant association with reduced survival (p = 0.00001, 0.0056, 0.03 and 0.009, respectively). The remaining analyzed factors (size, histological subtype, topography and immunophenotype) had no such association. Multivariate analysis (Jacard index) showed that the Miettinen degree of risk was the one that best correlated with prognosis. Conclusion: the risk criteria of Fletcher and Miettinen are important in assessing the prognosis of patients with gastrointestinal stromal tumors, especially the latter, which adds to the mitotic index and the presence of tumor necrosis. © 2015, Colegio Brasileiro de Cirurgioes. All right reserved.
de Barros F.,Hospital Federal do AndaraiRJ |
Nahoum G.P.,Hospital Federal do AndaraiRJ |
de Almeida B.J.,Hospital Universitario Gaffree Guinle
Revista do Colegio Brasileiro de Cirurgioes | Year: 2015
The gastrointestinal stromal tumor (GIST) is a rare mesenchymal tumor. One should pay special attention when the GIST comes in obese patients during surgery. The laparoscopic resections with standard techniques, such as gastric bypass, have been described with good results. However, GIST resection associated sleeve gastrectomy for the treatment of obesity is rare, but can be done safely, depending on the location of the tumor. © 2015, Colegio Brasileiro de Cirurgioes. All right reserved.
Garcia R.F.L.,University of the Region of Joinville |
Moreira S.,University of the Region of Joinville |
Ramos A.L.A.,Federal University of Rio de Janeiro |
Ferreira L.E.,University of the Region of Joinville |
And 11 more authors.
World Journal of Gastroenterology | Year: 2013
AIM: To analyze the role of rs12979860 and rs8099917 polymorphisms in hepatitis C virus (HCV) genotype 1 infection of Brazilians. METHODS: A total of 145 adult patients diagnosed with genotype 1 chronic hepatitis C (CHC) who had completed a 48-wk regimen of pegylated-interferon α-2a or -2b plus ribavirin combination therapy were recruited from six large urban healthcare centers and 199 healthy blood donors (controls) from a single site between January 2010 and January 2012. Data on the patients' response to treatment was collected. Polymerase chain reaction-restriction fragment length polymorphism genotyping of the interleukin (IL)28B gene fragment encompassing the single nucleotide polymorphisms (SNPs) rs12979860 (C/T) and rs8099917 (T/G) was carried out for 79 of the CHC patients and 199 of the controls. Bi-directional amplicon sequencing of the two SNPs was carried out for the remaining 66 CHC patients. RESULTS: SNP rs12979860 genotyping was successful in 99.5% of the controls and 97.2% of the CHC patients, whereas the SNP rs8099917 genotyping was successful in 95.5% of the controls and 100% of the CHC patients. The genotype and allele distributions for both rs12979860 and rs8099917 were significantly different between the control and CHC patient groups, with significantly higher genotype frequencies of CC and TT in the controls (P = 0.037 and 0.046, respectively) and of TT and GG in the CHC patients (P = 0.0009 and 0.0001, respectively). Analysis of the CHC patients who achieved sustained virological response (SVR) to treatment (n = 55) indicated that the rs12979860 C allele and CC genotype were predictors of SVR (P = 0.02). No significant correlation was found between rs8099917 genotypes and treatment response, but carriers of the T allele showed significantly higher rates of SVR (P = 0.02). Linkage disequilibrium analysis of the group that achieved SVR showed a significant association between rs12979860 and rs8099917 (P = 0.07). CONCLUSION: The higher allele frequency of rs12979860 C and rs8099917 T observed in non-HCVinfected individuals may indicate a potential protective role for these IL28B -related polymorphisms. © 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
Delmonico L.,Instituto Nacional Of Cancer |
Delmonico L.,State University of Rio de Janeiro |
Moreira A.D.S.,Instituto Oswaldo Cruz |
Franco M.F.,Hospital Universitario Gaffree Guinle |
And 8 more authors.
Human Pathology | Year: 2015
Summary Early detection of breast cancer increases the chances of cure, but the reliable identification of impalpable lesions is still a challenge. In spite of the advances in breast cancer detection, the molecular basis of impalpable lesions and the corresponding circulating biomarkers are not well understood. Impalpable lesions, classified by radiologists according to the Breast Imaging Reporting and Data System in the categories 3 and 4, can be either benign or malignant (slow growing or aggressive). In this article, we report the DNA methylation pattern in CDKN2A (p14ARF/p16INK4a) and in ATM gene promoters from 62 impalpable lesions, 39 peripheral blood samples, and 39 saliva samples, assessed by methylation-specific polymerase chain reaction method. ATM showed the greatest percentage of methylation in DNA from lesions (benign and malignant), blood (even with p16INK4a), and saliva, followed by p16INK4a and p14ARF. Among the malignant cases, ATM promoter was the most hypermethylated in lesion DNA and in blood and saliva DNAs, and p14ARF, the least. The highest percentage of p16INK4a methylation was found in the blood. Finally, our data are relevant because they were obtained using impalpable breast lesions from patients who were carefully recruited in 2 public hospitals of Rio de Janeiro. © 2015 Elsevier Inc. All rights reserved.
LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants [Documento de consenso de LACTRIMS para el tratamiento farmacológico de la esclerosis múltiple y sus variantes clínicas]
Abad P.,Hospital Metropolitano |
Nogales-Gaete J.,Hospital Barros Luco Trudeau |
Rivera V.,Baylor College of Medicine |
Cristiano E.,Hospital Italiano de Buenos Aires |
And 4 more authors.
Revista de Neurologia | Year: 2012
Introduction. Multiple sclerosis (MS) it is not considered any more a rare disease in Latin America. Most of the Latin American countries have reported moderate or lower prevalence data. However only very few countries have developed therapeutic guidelines. LACTRIMS prepared this consensus document with specific recommendations for the treatment of the disease. Development. Experts on treatment and clinical research on MS were invited by LACTRIMS in order to generate a initial document to be discussed in Quito, Ecuador. Several groups were organized in relation of the different clinical variants. These groups were coordinated by experts leaders and prepared a preliminary document that was discussed in Quito during July 8th and 9th, 2011. Finally the final version was submitted to the members and delegates of LACTRIMS in most of the Latin American countries who were able to make modifications and suggest changes to the final manuscript. Conclusions. Based on the different evidence levels and the AGREE criteria, the clinical variants were reviewed and recommendations were made for the use of drugs and different modifying disease therapeutic agents.